By jurisdiction
United Kingdom (MHRA)
Every compound we track that has a recorded status under United Kingdom (MHRA). Tap a name for the full picture, including the U.S. status and primary sources.
| Compound | Status here | Note |
|---|---|---|
| AOD-9604 | Restricted | No UK marketing authorisation (not in the MHRA products substance index); supply as a medicine would be unlicensed. |
| BPC-157 | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Cagrilintide | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| CJC-1295 | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Dihexa | Restricted | No UK marketing authorisation (not in the MHRA products substance index); supply as a medicine would be unlicensed. |
| Emideltide (DSIP) | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Epitalon | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| GHK-Cu | Restricted | No UK marketing authorisation; supply as a medicine is unlicensed, though copper tripeptide-1 remains a permitted cosmetic ingredient under GB cosmetics law. |
| Ipamorelin | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Kisspeptin-10 | Restricted | No UK marketing authorisation; the MHRA products database holds no kisspeptin product (its only matches are other medicines’ documents that mention kisspeptin). |
| KPV | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| LL-37 (cathelicidin) | Restricted | No UK marketing authorisation (not in the MHRA products substance index); supply as a medicine would be unlicensed. |
| Melanotan II | Restricted | No UK marketing authorisation; MHRA has repeatedly removed melanotan products from sale for over 10 years, though nasal sprays without medicinal claims are not generally regulated as medicines. |
| MOTS-c | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| NAD+ | Restricted | No UK marketing authorisation; injectable NAD+ is supplied only as an unlicensed ‘special’ on a prescriber’s order, while oral NAD+ is sold under food-supplement rules. |
| PT-141 (bremelanotide) | Restricted | No UK marketing authorisation (no bremelanotide product in the MHRA Products database); supply as a medicine would be unlicensed. |
| Retatrutide | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine - MHRA has seized unlicensed retatrutide products in enforcement operations. |
| Selank | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Semaglutide (compounded) | Restricted | Licensed prescription-only medicine; unlicensed copies may not be supplied where the licensed product can meet the patient’s need, and MHRA enforces against unlicensed semaglutide products. |
| Semax | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Sermorelin | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| SS-31 (elamipretide) | Restricted | No UK marketing authorisation (no result for elamipretide in the MHRA products database); supply as a medicine is unlicensed. |
| TB-500 (Thymosin Beta-4) | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Tesamorelin | Restricted | No UK marketing authorisation (no tesamorelin product in the MHRA Products database); supply as a medicine would be unlicensed. |
| Thymosin Alpha-1 | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Tirzepatide (compounded) | Restricted | Licensed prescription-only medicine; no legitimate compounding pathway; MHRA enforces against unlicensed product. |